Helix Biopharma Company Profile - Aug 07, 2011 by WrightReports

VIEWS: 35 PAGES: 11

Helix BioPharma Corp. (Helix) is a Canada-based biopharmaceutical company focused on cancer therapy. It is developing products for the treatment and prevention of cancer based on its technologies. Helix's product development initiatives include its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. As of July 31, 2010, it derived its revenue from distribution of product in Canada and royalty payments from Helsinn-Birex Pharmaceuticals Ltd. (Helsinn) relating to its license of the Company's Klean-Prep technology. The products distributed in Canada include Orthovisc and Monovisc, which are used for the treatments of osteoarthritis of the knee; Normacol and Klean-Prep, which are gastrointestinal products, and Imunovir, which is an immune system modulating drug. During the fiscal year ended July 31, 2010 (fiscal 2010), its product revenue derived mainly from the sale in Canada of Klean-Prep, Orthovisc and Monovisc. During fiscal 2010, it launched new product Monovisc.

More Info
									Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Helix Biopharma Corp
                                                                                        440 Wheelers Farms Road
                                                                                        Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in Canadian Dollars

                                 Wright Quality Rating:DCNN                                 Key Data

   Helix BioPharma Corp. (Helix) is a Canada-based biopharmaceutical company focused        Ticker:
   on cancer therapy. It is developing products for the treatment and prevention of         HBP
   cancer based on its technologies. Helix's product development initiatives include its
   L-DOS47 and Topical Interferon Alpha-2b new drug candidates. As of July 31, 2010,        2010 Sales:
   it derived its revenue from distribution of product in Canada and royalty payments
                                                                                            4,434,000
   from Helsinn-Birex Pharmaceuticals Ltd. (Helsinn) relating to its license of the
   Company's Klean-Prep technology. The products distributed in Canada include
   Orthovisc and Monovisc, which are used for the treatments of osteoarthritis of the       Major Industry:
   knee; Normacol and Klean-Prep, which are gastrointestinal products, and Imunovir,        Drugs, Cosmetics & Health
   which is an immune system modulating drug. During the fiscal year ended July 31,         Care
   2010 (fiscal 2010), its product revenue derived mainly from the sale in Canada of
   Klean-Prep, Orthovisc and Monovisc. During fiscal 2010, it launched new product          Sub Industry:
   Monovisc.                                                                                Ethical Drug Manufacturers
                       Stock Chart                                 Officers
                                                         Chairman & Chief Executive         Country:
                                                              Dr. Donald H. Segal           Canada

                                                         President & Chief Operating        Currency:
                                                                   Officer
                                                                                            Canadian Dollars
                                                               John M. Docherty

                                                                                            Fiscal Year Ends:
                                                              Chief Financial Officer
                                                               Photios Michalargias         July


                                                                   Secretary                Employees
                                                                Kenneth A. Cawkell          28

                                                                                            Exchanges:
                                                                                            TOR FRA

                                                                                            Share Type:
                                                                                            Common

                                                                                            Market Capitalization:
             Stock Price (8/5/2011): 2.53
                       
								
To top